Bioenvision (NASDAQ:BIVN)
Historical Stock Chart
From Jul 2019 to Jul 2024
![Click Here for more Bioenvision Charts. Click Here for more Bioenvision Charts.](/p.php?pid=staticchart&s=N%5EBIVN&p=8&t=15)
Bioenvision (NASDAQ:BIVN) announced today that it will
participate in the 2005 UBS Global Life Sciences Conference scheduled
for September 26-29, 2005, in New York City. Dr. Christopher B. Wood,
Chairman & CEO, will represent the Company at this conference. "We are
pleased to be invited to present again at the UBS Global Life Sciences
Conference which has become one of the leading conferences in the
industry" said Dr. Wood.
The conference will be held at the Grand Hyatt New York.
Bioenvision's presentation is scheduled for 9:30 am (EDT) on
Wednesday, September 28, 2005. Audio transmission of the presentation
will be available live via the internet. To access the presentation,
please visit http://www.ibb.ubs.com (click on the "Conferences" icon
in the center right of the page and then follow the link for the
Global Life Sciences Conference). A replay of the presentation will
begin three hours after the actual presentation time and will be
available until October 28, 2005.
About Bioenvision
Bioenvision's primary focus is the acquisition, development and
distribution of compounds and technologies for the treatment of
cancer. Bioenvision has a broad pipeline of products for the treatment
of cancer, including: Clofarabine (in co-development with Genzyme
Corporation), Modrenal(R) (for which Bioenvision has obtained
regulatory approval for marketing in the United Kingdom for the
treatment of post-menopausal breast cancer following relapse to
initial hormone therapy), and other products in clinical trials.
Bioenvision is also developing anti-infective technologies, including
the OLIGON technology; an advanced biomaterial that has been
incorporated into various FDA approved medical devices. For more
information on Bioenvision please visit our Web site at
www.bioenvision.com.
Certain statements contained herein are "forward-looking"
statements (as such term is defined in the Private Securities
Litigation Reform Act of 1995). Because these statements include risks
and uncertainties, actual results may differ materially from those
expressed or implied by such forward-looking statements. Specifically,
factors that could cause actual results to differ materially from
those expressed or implied by such forward-looking statements include,
but are not limited to: risks associated with preclinical and clinical
developments in the biopharmaceutical industry in general and in
Bioenvision's compounds under development in particular; the potential
failure of Bioenvision's compounds under development to prove safe and
effective for treatment of disease; uncertainties inherent in the
early stage of Bioenvision's compounds under development; failure to
successfully implement or complete clinical trials; failure to receive
marketing clearance from regulatory agencies for our compounds under
development; acquisitions, divestitures, mergers, licenses or
strategic initiatives that change Bioenvision's business, structure or
projections; the development of competing products; uncertainties
related to Bioenvision's dependence on third parties and partners; and
those risks described in Bioenvision's filings with the SEC.
Bioenvision disclaims any obligation to update these forward-looking
statements.